Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells

Research published in the July 22 issue of Nature Biotechnologyshows for the first time that a novel genomic sequencing method called Smart-Seq can help scientists conduct in-depth analyses of clinically relevant single cells. Smart-Seq has many possible applications, including helping scientists to better understand the complexities of tumor development. This is vitally important as many clinically important cells exist only in small numbers and require single cell analysis. The study was conducted by a team of researchers from the Ludwig Institute for Cancer Research, the Karolinska Institutet in Sweden, the University of California, San Diego and Illumina Inc.

“While our results are preliminary, we showed that it is possible to do studies of individual, clinically relevant cells,” says biomedical scientist Rickard Sandberg, researcher at the Ludwig Institute for Cancer Research and principal investigator at the Department of Cell and Molecular Biology, Karolinska Institutet. “Cancer researchers around the world will now be able to analyze these cells more systematically to enable them to produce better methods of diagnosis and therapy in the future.”

Previous research showed that it is common for one gene to give rise to several forms of the same protein through different cut-and-paste configurations of its raw copy. The phenomenon, known as splicing, means that cells from the same tissue are not so homogenous as previously thought.

The research team has now taken its study a step further and developed a method for the complete mapping of the gene expression of individual cells. In showing which genes are active, it is now possible to accurately describe and study differences in gene expression between individual cells from the same tissue.

“Scientists have been waiting for a long time for such a method to come along, but technical limitations have made it difficult to produce a sufficiently sensitive and robust method,” says Dr. Sandberg. “The method has several areas of applications including cancer research where it can be used to study which cell types form cancer tumors in individual patients.”

In the study, scientists studied tumor cells in the blood system of a patient with recurring malignant melanoma. Once they had identified the tumor cells in a regular blood test, the team used Smart-Seq to analyze their gene expression. By using this method, researchers could show that the tumor cells had activated many important membrane proteins that are understood to be responsible for their ability to evade the body’s monitoring system and spread in the blood or lymph.

Reference:

Ramsköld D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, Daniels GA, Khrebtukova I, Loring JF, Laurent LC, Schroth GP, Sandberg R. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol. 2012 Jul 22. doi: 10.1038/nbt.2282. [Epub ahead of print] PubMed PMID: 22820318.


 

Incoming search terms:

  • full-length mrna-seq from single-cell levels of rna and individual circulating tumor cells
  • Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells data
  • circulating mrna sequencing
  • single cell rnaseq
  • single cell rna-seq
  • single cell seq
  • cancer mrna circulating 2013
  • full length mrna
  • single cell rna seq
  • Full-Length mRNA-Seq from single cell levels of RNA and individual circulating tumor cells

Subscribe NGS Updates

Share This Article

You might also like

Leave a Reply

Submit Comment

© 2024 Genomics Gateway. All rights reserved.